LOUISVILLE, Ky.--(BUSINESS WIRE)--Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that its abstract summarizing the preclinical data on an inhibitor of glycolysis has been selected for oral presentation at the 102nd American Association for Cancer Research (AACR) Annual Meeting to be held April 2 – April 6, 2011 in Orlando, Florida.
